In the context of metastatic cancer, there are currently over 200 clinical trials investigating the safety and efficacy of various therapeutics targeting the IL-6 pathway, including IL-6 direct inhibitors (i.e., Siltuximab), IL-6Rα direct inhibitors (i.e., Tocilizumab), IL-6R gp130 direct inhibitors (i.e., Raloxifene), and JAK inhibitors (i.e., Ruxolitinib) (Clinical Trials Registry, www.clinicaltrials.gov, accessed date: 21 May 2021) (Table 1). Here, IL6 is linked to metastatic malignant neoplasm.